Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42) 42
oncology (41) 41
female (39) 39
index medicus (31) 31
middle aged (23) 23
cancer (19) 19
aged (18) 18
adult (16) 16
immunology (14) 14
prognosis (14) 14
endometrial cancer (13) 13
hematology, oncology and palliative medicine (13) 13
immunotherapy (13) 13
neoplasm staging (13) 13
carcinoma (12) 12
expression (12) 12
obstetrics & gynecology (12) 12
ovarian cancer (12) 12
umcg approved (12) 12
endometrial neoplasms - pathology (10) 10
risk factors (10) 10
survival (10) 10
immunohistochemistry (9) 9
obstetrics and gynecology (9) 9
p53 (9) 9
t-lymphocytes, cytotoxic - immunology (9) 9
aged, 80 and over (8) 8
colorectal-cancer (8) 8
dendritic cells (8) 8
ovarian neoplasms - immunology (8) 8
research (8) 8
cervical cancer (7) 7
chemotherapy (7) 7
endometrial neoplasms - therapy (7) 7
health aspects (7) 7
medicine, research & experimental (7) 7
ovarian neoplasms - pathology (7) 7
treatment outcome (7) 7
amino acid sequence (6) 6
animals (6) 6
care and treatment (6) 6
cervical-cancer (6) 6
cytotoxic t lymphocyte (6) 6
external-beam radiotherapy (6) 6
follow-up studies (6) 6
immunization (6) 6
lymphocytes (6) 6
molecular sequence data (6) 6
ovarian-cancer (6) 6
randomized-trial (6) 6
regulatory t-cells (6) 6
survival analysis (6) 6
t-lymphocytes - immunology (6) 6
tumor (6) 6
tumor suppressor protein p53 - immunology (6) 6
tumor-infiltrating lymphocytes (6) 6
tumors (6) 6
antigens (5) 5
cancer vaccines - immunology (5) 5
endometrial neoplasms - mortality (5) 5
human (5) 5
human papillomavirus (5) 5
lymphocytes, tumor-infiltrating - immunology (5) 5
patients (5) 5
radiotherapy (5) 5
surgery (5) 5
t cells (5) 5
uterine cervical neoplasms - pathology (5) 5
young adult (5) 5
analysis (4) 4
breast-cancer (4) 4
cancer patients (4) 4
cells (4) 4
clinical trials (4) 4
down-regulation (4) 4
endometrial neoplasms - immunology (4) 4
flow cytometry (4) 4
immune-responses (4) 4
immunity, cellular (4) 4
immunogenicity (4) 4
metaanalysis (4) 4
metastasis (4) 4
molecular diagnostics (4) 4
neoplasm grading (4) 4
neoplasm invasiveness (4) 4
netherlands (4) 4
prognostic-significance (4) 4
radiation (4) 4
registries (4) 4
retrospective studies (4) 4
uterine cervical neoplasms - surgery (4) 4
vaccine (4) 4
vaccines (4) 4
wild-type p53 (4) 4
women (4) 4
adenocarcinoma, clear cell - pathology (3) 3
adolescent (3) 3
biochemistry & molecular biology (3) 3
biopsy (3) 3
cancer research (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
by Gooden, M.J.M and De Bock, G.H and Leffers, N and Daemen, T and Nijman, H.W
British Journal of Cancer, ISSN 0007-0920, 06/2011, Volume 105, Issue 1, pp. 93 - 103
BACKGROUND: Tumour- infiltrating lymphocytes (TILs) are often found in tumours, presumably reflecting an immune response against the tumour. We carried out a... 
meta-analysis | tumour-infiltrating lymphocytes | prognosis | IMMUNE CELLS | LEUKOCYTE INFILTRATION | ANTIGEN-PROCESSING MACHINERY | MHC CLASS-I | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | COLORECTAL-CANCER | FAVORABLE PROGNOSIS | REGULATORY T-CELLS | CYCLOOXYGENASE-2 EXPRESSION | ADVERSE PROGNOSIS | Neoplasms - diagnosis | Prognosis | Lymphocytes, Tumor-Infiltrating - pathology | Neoplasms - immunology | Humans | Molecular Diagnostics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up
by Colombo, Nicoletta and Creutzberg, C and Amant, F and Bosse, T and González-Martón, A and Ledermann, J and Marth, C and Nout, R and Querleu, D and Mirza, M.R and Sessa, C and Abal, M and Altundag, O and Amant, F and Banerjee, S and Bosse, T and Casado, A and De Agustín, L.C and Cibula, D and Colombo, N and Creutzberg, C and Del Campo, J.-M and Emons, G and Goffin, F and González-Martín, A and Greggi, S and Haie-Meder, C and Katsaros, D and Kesic, V and Kurzeder, C and Lax, S and Lécuru, F and Ledermann, J and Levy, T and Lorusso, D and Mäenpää, J and Marth, C and Matias-Guiu, X and Morice, P and Nijman, H.W and Nout, R and Powell, M and Querleu, D and Mirza, M.R and Reed, N and Rodolakis, A and Salvesen, H and Sehouli, J and Sessa, C and Taylor, A and Westermann, A and Zeimet, A.G and ESMO-ESGO-ESTRO Endometrial Consen and ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
Annals of Oncology, ISSN 0923-7534, 01/2016, Volume 27, Issue 1, pp. 16 - 41
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological... 
Practice guideline | Adjuvant | Treatment | Endometrial neoplasms | Surgery | Consensus | treatment | WHOLE-ABDOMINAL-IRRADIATION | CLINICAL STAGE-I | consensus | PHASE-III TRIAL | LYMPHVASCULAR SPACE INVOLVEMENT | EXTERNAL-BEAM RADIOTHERAPY | UTERINE SEROUS CARCINOMA | CLEAR-CELL | ONCOLOGY | adjuvant | POSTOPERATIVE RADIATION-THERAPY | practice guideline | FERTILITY-SPARING-MANAGEMENT | endometrial neoplasms | surgery | INDEPENDENT RISK-FACTOR | Mass Screening | Follow-Up Studies | Early Detection of Cancer | Humans | Endometrial Neoplasms - therapy | Female | Combined Modality Therapy | Endometrial Neoplasms - diagnosis | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
by Leffers, N and Lambeck, A.J.A and Gooden, M.J and Hoogeboom, B.N and Wolf, R and Hamming, I.E and Hepkema, B.G and Willemse, P.H and Molmans, B.H and Hollema, H and jfhout, J.W and Sluiter, W.J and Valentijn, A.R and Fathers, L.M and Oostendorp, J and Zee, A.G. van der and Melief, C.J and Burg, S.H. van der and Daemen, T and Nijman, H.W
International Journal of Cancer, ISSN 0020-7136, 2009, Volume 125, Issue 9, pp. 2104 - 2113
The prognosis of ovarian cancer, the primary cause of death from gynecological malignancies, has only modestly improved over the last decades. Immunotherapy is... 
vaccine | ovarian cancer | immunotherapy | p53 | Vaccine | Immunotherapy | Ovarian cancer | SURVIVAL | CERVICAL-CANCER | TUMOR-ANTIGEN | BREAST-CANCER | ONCOLOGY | COLORECTAL-CANCER | ANTI-P53 ANTIBODIES | REGULATORY T-CELLS | SELF-TOLERANCE | LYMPHOCYTES | Amino Acid Sequence | Immunization | Lymphocyte Activation | Humans | Middle Aged | Molecular Sequence Data | Cancer Vaccines - adverse effects | Tumor Suppressor Protein p53 - immunology | Pregnancy | Cancer Vaccines - immunology | Peptide Fragments - immunology | Ovarian Neoplasms - therapy | Adult | Female | T-Lymphocytes - immunology | Aged | Interferon-gamma - biosynthesis | Cell Movement | Ovarian Neoplasms - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET
by Hartimath, SV and Draghiciu, O and Daemen, T and Nijman, H.W and van Waarde, A and Dierckx, R.A.J.O and de Vries, E.F.J
Molecular Imaging and Biology, ISSN 1536-1632, 12/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Compliance with adjuvant treatment guidelines in endometrial cancer: Room for improvement in high risk patients
by Eggink, F.a and Mom, C.h and Boll, D and Ezendam, N.P.M and Kruitwagen, R.F.P.M and Pijnenborg, J.M.A and van der Aa, M.A and Nijman, H.W
Gynecologic Oncology, ISSN 0090-8258, 08/2017, Volume 146, Issue 2, pp. 380 - 385
Objectives: Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
by Bosse, T and Nout, R.A and Stelloo, E and Dreef, E and Nijman, H.W and Jürgenliemk-Schulz, I.M and Jobsen, J.J and Creutzberg, C.L and Smit, V.T.H.B.M
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 15, pp. 2602 - 2610
Abstract Background L1 cell adhesion molecule (L1CAM) expression has been implicated as risk factor for disease recurrence in endometrial cancer (EC), most... 
Hematology, Oncology and Palliative Medicine | Endometrial cancer | L1CAM | PORTEC | Prognostic marker | KAPPA-B ACTIVATION | ADENOCARCINOMA CELLS | RANDOMIZED-TRIAL | OVARIAN-CARCINOMA | GASTRIC-CANCER | INVASIVE FRONT | RADIOTHERAPY | UP-REGULATION | EXPRESSION | ONCOLOGY | Immunohistochemistry | Multivariate Analysis | Predictive Value of Tests | Prognosis | Neoplasm Recurrence, Local - metabolism | Humans | Middle Aged | Risk Factors | Endometrial Neoplasms - metabolism | Kaplan-Meier Estimate | Postoperative Period | Treatment Outcome | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Randomized Controlled Trials as Topic | Radiotherapy - methods | Aged, 80 and over | Endometrial Neoplasms - therapy | Adult | Endometrial Neoplasms - pathology | Female | Aged | Neural Cell Adhesion Molecule L1 - metabolism | Neoplasm Staging | Patient outcomes | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
by de Boer, Stephanie M, Dr and Powell, Melanie E, MD and Mileshkin, Linda, MD and Katsaros, Dionyssios, Prof and Bessette, Paul, Prof and Haie-Meder, Christine, MD and Ottevanger, Petronella B, MD and Ledermann, Jonathan A, Prof and Khaw, Pearly, MD and Colombo, Alessandro, MD and Fyles, Anthony, Prof and Baron, Marie-Helene, MD and Kitchener, Henry C, Prof and Nijman, Hans W, Prof and Kruitwagen, Roy F, Prof and Nout, Remi A, MD and Verhoeven-Adema, Karen W, PhD and Smit, Vincent T, Prof and Putter, Hein, Prof and Creutzberg, Carien L, Prof and PORTEC Study Grp and PORTEC study group
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1114 - 1126
Summary Background About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant metastases and endometrial... 
Hematology, Oncology and Palliative Medicine | CARCINOMA PATIENTS | EXTERNAL-BEAM RADIOTHERAPY | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | PELVIC RADIATION-THERAPY | EUROPEAN-ORGANIZATION | STAGE-I | OVARIAN-CANCER | INTERMEDIATE-RISK | III TRIAL | CHEMOTHERAPY | Endometrial Neoplasms - radiotherapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Gastrointestinal Diseases - etiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Adenocarcinoma, Clear Cell - radiotherapy | Chemoradiotherapy, Adjuvant - adverse effects | Nervous System Diseases - diagnosis | Case-Control Studies | Gastrointestinal Diseases - diagnosis | Cisplatin - administration & dosage | Neoplasm Grading | Radiotherapy, Adjuvant - adverse effects | Cystadenocarcinoma, Serous - therapy | Female | Paclitaxel - administration & dosage | Cystadenocarcinoma, Serous - secondary | Neoplasm Invasiveness | Carboplatin - administration & dosage | Survival Rate | Lymphatic Metastasis | Hematologic Diseases - diagnosis | Adenocarcinoma, Clear Cell - secondary | Hematologic Diseases - etiology | Adenocarcinoma, Clear Cell - therapy | Endometrial Neoplasms - therapy | Nervous System Diseases - etiology | Quality of Life | Endometrial Neoplasms - pathology | Aged | Neoplasm Staging | Cystadenocarcinoma, Serous - radiotherapy | Endometrial cancer | Oncology, Experimental | Radiation | Metastasis | Research | Radiotherapy | Health aspects | Risk factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
by Dijkgraaf, E.M and Santegoets, S.J.A.M and Reyners, A.K.L and Goedemans, R and Wouters, M.C.A and Kenter, G.G and van Erkel, A.R and van Poelgeest, M.I.E and Nijman, H.W and van der Hoeven, J.J.M and Welters, M.J.P and van der Burg, S.H and Kroep, Judith R
Annals of Oncology, ISSN 0923-7534, 10/2015, Volume 26, Issue 10, pp. 2141 - 2149
The immune system is important in epithelial ovarian cancer (EOC). Interleukin-6 is associated with chemoresistance and an immune-suppressive tumor... 
Tumor immunity | Immunotherapy | Chemoresistance | Interleukin-6 | Ovarian cancer | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Receptors, Interleukin-6 - antagonists & inhibitors | Cystadenocarcinoma, Serous - pathology | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Adenocarcinoma, Mucinous - blood | Interleukin-6 - blood | Doxorubicin - analogs & derivatives | Adult | Female | Adenocarcinoma, Mucinous - drug therapy | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Cystadenocarcinoma, Serous - blood | CA-125 Antigen - blood | Enzyme-Linked Immunosorbent Assay | Neoplasm Invasiveness | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Interferon-alpha - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Interferon-gamma - blood | Adenocarcinoma, Clear Cell - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment
by Versluis, M.A.C and Marchal, S and Plat, A and de Bock, G.H and van Hall, T and de Bruyn, M and Hollema, H and Nijman, H.W
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 285 - 295
Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative prognostic marker in cancer. This apparent discrepancy may be due to... 
Natural Killer cells | Cancer immunology | Endometrial neoplasm | HLA-E antigen | Cytotoxic T lymphocyte | Tumour-infiltrating lymphocytes | HLA CLASS-I | PROTEIN | RECOGNITION | VARIANTS | IMMUNE ESCAPE | PEPTIDE REPERTOIRE | CD94/NKG2A | RECEPTORS | EXPRESSION | BINDING | ONCOLOGY | Immunohistochemistry | Multivariate Analysis | Up-Regulation | Biomarkers, Tumor - analysis | Endometrial Neoplasms - mortality | Tissue Array Analysis | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Tumor Microenvironment | Treatment Outcome | Histocompatibility Antigens Class I - analysis | Disease Progression | Disease-Free Survival | Endometrial Neoplasms - immunology | Time Factors | Endometrial Neoplasms - therapy | Killer Cells, Natural - immunology | Endometrial Neoplasms - pathology | Female | T-Lymphocytes - immunology | Lymphocytes, Tumor-Infiltrating - immunology | Killer cells | Histocompatibility antigens | Endometrial cancer | Analysis | HLA histocompatibility antigens | T cells | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer
by de Boer, S and Powell, M.E and Mileshkin, L and Katsaros, D and Bessette, P and Haie-Meder, C and Ottevanger, P.B and Ledermann, J.A and Khaw, P and Colombo, A and Fyles, A and Baron, M.H and Jurgenliemk-Schulz, I and Kitchener, H and Nijman, H.W and Kruitwagen, R.F and Smit, V.T and Nout, R.A and Putter, H and Creutzberg, C.L
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 09/2019, Volume 105, Issue 1, pp. S1 - S2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
by Wortman, B.G and Creutzberg, Carien and Putter, Hein and Jürgenliemk-Schulz, Ina-M and Jobsen, Jan and Lutgens, Ludy and Steen-Banasik, Elzbieta and Mens, J.W.M and Slot, Annerie and Kroese, Stenfert and van Triest, B and Nijman, Hans and Stelloo, E and Bosse, Tjalling and Boer, Stephanie and Putten, Wim and Smit, Vincent and Nout, R.A and PORTEC Study Grp and PORTEC Study Group and for the PORTEC Study Group
British Journal of Cancer, ISSN 0007-0920, 01/2018, Volume 119, Issue 9, pp. 1067 - 1074
textabstractBackground: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam... 
PHASE-III TRIAL | CANCER MRC ASTEC | LYMPHVASCULAR SPACE INVOLVEMENT | EXTERNAL-BEAM RADIOTHERAPY | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | OPERATIVE RADIATION-THERAPY | PELVIC RADIOTHERAPY | RANDOMIZED-TRIAL | QUALITY-OF-LIFE | PROGNOSTIC-SIGNIFICANCE | Endometrial Neoplasms - radiotherapy | Radiotherapy Dosage | Humans | Middle Aged | Neural Cell Adhesion Molecule L1 - genetics | Treatment Outcome | Vagina - radiation effects | Tumor Suppressor Protein p53 - genetics | Patient Selection | Pelvis - radiation effects | Endometrial Neoplasms - genetics | Radiotherapy, Adjuvant - methods | Survival Analysis | Endometrial Neoplasms - pathology | Female | Aged | Brachytherapy | Neoplasm Staging | Endometrial cancer | p53 Protein | Health risks | Vagina | Radiation therapy | Risk analysis | Patients | Risk factors | Metastases | Pathology | Randomization | Risk assessment | Endometrium | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer
by de Jong, R.A and Leffers, N and Boezen, H.M and ten Hoor, K.A and van der Zee, A.G.J and Hollema, H and Nijman, H.W
Gynecologic Oncology, ISSN 0090-8258, 2009, Volume 114, Issue 1, pp. 105 - 110
Abstract Objective Presence of tumor-infiltrating lymphocytes (TIL) is of prognostic importance in a variety of malignancies. This study aims to determine the... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Endometrial cancer | Tumor-infiltrating lymphocytes | Cytotoxic T-lymphocyte | SURVIVAL | STAGE | OVARIAN-CANCER | UMCG Approved | MELANOMA | COLORECTAL-CANCER | INCREASE | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | CARCINOMA | EXPRESSION | OBSTETRICS & GYNECOLOGY | ONCOLOGY | Immunohistochemistry | Lymph Node Excision | Antigens, CD - immunology | CD8-Positive T-Lymphocytes - pathology | Prognosis | Endometrial Neoplasms - mortality | Humans | Survivors | Survival Rate | Leukocyte Common Antigens - immunology | Endometrial Neoplasms - immunology | Lymphocytes, Tumor-Infiltrating - pathology | Microarray Analysis | Endometrial Neoplasms - surgery | Forkhead Transcription Factors - analysis | Endometrial Neoplasms - pathology | Female | T-Lymphocytes - immunology | Retrospective Studies | T-Lymphocytes - pathology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Lymphocytes, Tumor-Infiltrating - immunology | T cells | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative
by Edmondson, R.J and Crosbie, E.J and Nickkho-Amiry, M and Kaufmann, A and Stelloo, E and Nijman, H.W and Leary, A and Auguste, A and Mileshkin, L and Pollock, P and MacKay, H.J and Powell, M.E and Bosse, T and Creutzberg, C.L and Kitchener, H.C
Gynecologic Oncology, ISSN 0090-8258, 08/2017, Volume 146, Issue 2, pp. 327 - 333
The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular... 
Prognosis | Endometrial cancer | pp63 | Molecular profiling | L1CAM | p21 | Pole | p53 | WORKING | CLASSIFICATION | P63 | EXPRESSION | CARCINOMA | OBSTETRICS & GYNECOLOGY | ONCOLOGY | Immunohistochemistry | Neoplasms, Cystic, Mucinous, and Serous - metabolism | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Endometrial Neoplasms - metabolism | Tumor Suppressor Protein p53 - genetics | Carcinoma, Endometrioid - metabolism | Neoplasms, Cystic, Mucinous, and Serous - genetics | Young Adult | Neoplasm Grading | Endometrial Neoplasms - genetics | Phosphoproteins | Aged, 80 and over | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Adult | Female | Proto-Oncogene Proteins c-mdm2 - metabolism | Carcinoma, Endometrioid - genetics | Tumor Suppressor Proteins - metabolism | Neoplasms, Cystic, Mucinous, and Serous - pathology | Signal Transduction | Adenocarcinoma, Clear Cell - metabolism | Neoplasm Invasiveness | Gene Silencing | Proportional Hazards Models | Tumor Suppressor Protein p53 - metabolism | Transcription Factors - metabolism | Carcinoma, Endometrioid - mortality | Cell Line, Tumor | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Mutation | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Neoplasms, Cystic, Mucinous, and Serous - mortality | Tumor proteins | Health aspects | Risk factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights